Valneva reports net income for the first three months of 2024 of 58.9 million euros, reflecting the sale of the Priority Review Voucher (PRV), versus a loss of 18.1 million a year earlier, with adjusted EBITDA up from -12.3 to +73 million.

The vaccines company saw total sales fall by 2% to 32.8 million euros, with product sales stable at 32.1 million, including 16.6 million for Ixiaro/Jespect (Japanese encephalitis) and 11.3 million for Dukoral (cholera).

Valneva confirms that it expects total sales for the current year to be between 170 and 190 million euros, including 160 to 180 million thanks to growth in sales of its proprietary vaccines.

"For the remainder of the year, we expect to continue to benefit from the recovery in the travel industry, and at the same time achieve the various R&D milestones we have set ourselves", says CFO Peter Bühler.

Copyright (c) 2024 CercleFinance.com. All rights reserved.